124 related articles for article (PubMed ID: 33811738)
1. Association between one-time prostate-specific antigen (PSA) test with free/total PSA ratio and prostate cancer mortality: A 30-year prospective cohort study.
Lundgren PO; Kjellman A; Norming U; Gustafsson O
BJU Int; 2021 Oct; 128(4):490-496. PubMed ID: 33811738
[TBL] [Abstract][Full Text] [Related]
2. Prostate cancer risk assessment in men with an initial P.S.A. below 3 ng/mL: results from the Göteborg randomized population-based prostate cancer screening trial.
Frånlund M; Arnsrud Godtman R; Carlsson SV; Lilja H; Månsson M; Stranne J; Hugosson J
Scand J Urol; 2018 Aug; 52(4):256-262. PubMed ID: 30241447
[TBL] [Abstract][Full Text] [Related]
3. A "PSA pyramid" for men with initial prostate-specific antigen ≤3 ng/ml: a plea for individualized prostate cancer screening.
Randazzo M; Beatrice J; Huber A; Grobholz R; Manka L; Chun FK; Recker F; Kwiatkowski M
Eur Urol; 2015 Oct; 68(4):591-7. PubMed ID: 24794075
[TBL] [Abstract][Full Text] [Related]
4. Risk of Prostate Cancer-related Death Following a Low PSA Level in the PLCO Trial.
Landy R; Houghton LC; Berg CD; Grubb RL; Katki HA; Black A
Cancer Prev Res (Phila); 2020 Apr; 13(4):367-376. PubMed ID: 31996370
[TBL] [Abstract][Full Text] [Related]
5. Early detection of high-grade prostate cancer using digital rectal examination (DRE) in men with a prostate-specific antigen level of <2.5 ng/mL and the risk of death.
Hattangadi JA; Chen MH; D'Amico AV
BJU Int; 2012 Dec; 110(11):1636-41. PubMed ID: 22757982
[TBL] [Abstract][Full Text] [Related]
6. Influence of blood prostate specific antigen levels at age 60 on benefits and harms of prostate cancer screening: population based cohort study.
Carlsson S; Assel M; Sjoberg D; Ulmert D; Hugosson J; Lilja H; Vickers A
BMJ; 2014 Mar; 348():g2296. PubMed ID: 24682399
[TBL] [Abstract][Full Text] [Related]
7. Pretreatment PSA velocity and risk of death from prostate cancer following external beam radiation therapy.
D'Amico AV; Renshaw AA; Sussman B; Chen MH
JAMA; 2005 Jul; 294(4):440-7. PubMed ID: 16046650
[TBL] [Abstract][Full Text] [Related]
8. Usefulness of the ratio free/total prostate-specific antigen in addition to total PSA levels in prostate cancer screening.
Reissigl A; Klocker H; Pointner J; Fink K; Horninger W; Ennemoser O; Strasser H; Colleselli K; Höltl L; Bartsch G
Urology; 1996 Dec; 48(6A Suppl):62-6. PubMed ID: 8973702
[TBL] [Abstract][Full Text] [Related]
9. Association of Treatment With 5α-Reductase Inhibitors With Time to Diagnosis and Mortality in Prostate Cancer.
Sarkar RR; Parsons JK; Bryant AK; Ryan ST; Kader AK; McKay RR; D'Amico AV; Nguyen PL; Hulley BJ; Einck JP; Mundt AJ; Kane CJ; Murphy JD; Rose BS
JAMA Intern Med; 2019 Jun; 179(6):812-819. PubMed ID: 31058923
[TBL] [Abstract][Full Text] [Related]
10. Screening Prostate-specific Antigen Concentration and Prostate Cancer Mortality: The Korean Heart Study.
Mok Y; Kimm H; Shin SY; Jee SH; Platz EA
Urology; 2015 May; 85(5):1111-1116. PubMed ID: 25917733
[TBL] [Abstract][Full Text] [Related]
11. Association between PSA values and surveillance quality after prostate cancer surgery.
Chapman CH; Caram MEV; Radhakrishnan A; Tsodikov A; Deville C; Burns J; Zaslavsky A; Chang M; Leppert JT; Hofer T; Sales AE; Hawley ST; Hollenbeck BK; Skolarus TA
Cancer Med; 2019 Dec; 8(18):7903-7912. PubMed ID: 31691526
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic value of percent free prostate-specific antigen: retrospective analysis of a population-based screening study with emphasis on men with PSA levels less than 3.0 ng/mL.
Törnblom M; Norming U; Adolfsson J; Becker C; Abrahamsson PA; Lilja H; Gustafsson O
Urology; 1999 May; 53(5):945-50. PubMed ID: 10223488
[TBL] [Abstract][Full Text] [Related]
13. Contamination in control group led to no effect of PSA-based screening on prostate cancer mortality at 9 years follow-up: Results of the French section of European Randomized Study of Screening for Prostate Cancer (ERSPC).
Villers A; Bessaoud F; Trétarre B; Grosclaude P; Malavaud B; Rebillard X; Iborra F; Daubisse L; Malavaud S; Roobol M; Heijnsdijk EA; de Koning HJ; Hugosson J; Rischmann P; Soulié M
Prog Urol; 2020 Apr; 30(5):252-260. PubMed ID: 32197936
[TBL] [Abstract][Full Text] [Related]
14. Prostate cancer screening practices in a large, integrated health system: 2007-2014.
Misra-Hebert AD; Hu B; Klein EA; Stephenson A; Taksler GB; Kattan MW; Rothberg MB
BJU Int; 2017 Aug; 120(2):257-264. PubMed ID: 28139034
[TBL] [Abstract][Full Text] [Related]
15. Prostate-specific antigen nadir and cancer-specific mortality following hormonal therapy for prostate-specific antigen failure.
Stewart AJ; Scher HI; Chen MH; McLeod DG; Carroll PR; Moul JW; D'Amico AV
J Clin Oncol; 2005 Sep; 23(27):6556-60. PubMed ID: 16170163
[TBL] [Abstract][Full Text] [Related]
16. Nomogram Predicting Prostate Cancer-specific Mortality for Men with Biochemical Recurrence After Radical Prostatectomy.
Brockman JA; Alanee S; Vickers AJ; Scardino PT; Wood DP; Kibel AS; Lin DW; Bianco FJ; Rabah DM; Klein EA; Ciezki JP; Gao T; Kattan MW; Stephenson AJ
Eur Urol; 2015 Jun; 67(6):1160-1167. PubMed ID: 25301759
[TBL] [Abstract][Full Text] [Related]
17. Cumulative probability of prostate cancer detection in biopsy according to free/total PSA ratio in men with total PSA levels of 2.1-10.0 ng/ml at population screening.
Kitagawa Y; Ueno S; Izumi K; Kadono Y; Konaka H; Mizokami A; Namiki M
J Cancer Res Clin Oncol; 2014 Jan; 140(1):53-9. PubMed ID: 24165867
[TBL] [Abstract][Full Text] [Related]
18. Prostate-specific antigen-based serial screening may decrease prostate cancer-specific mortality.
Efstathiou JA; Chen MH; Catalona WJ; McLeod DG; Carroll PR; Moul JW; Roehl KA; D'Amico AV
Urology; 2006 Aug; 68(2):342-7. PubMed ID: 16904449
[TBL] [Abstract][Full Text] [Related]
19. Long-term prostate-specific antigen velocity in improved classification of prostate cancer risk and mortality.
Ørsted DD; Bojesen SE; Kamstrup PR; Nordestgaard BG
Eur Urol; 2013 Sep; 64(3):384-93. PubMed ID: 23398767
[TBL] [Abstract][Full Text] [Related]
20. Strategy for detection of prostate cancer based on relation between prostate specific antigen at age 40-55 and long term risk of metastasis: case-control study.
Vickers AJ; Ulmert D; Sjoberg DD; Bennette CJ; Björk T; Gerdtsson A; Manjer J; Nilsson PM; Dahlin A; Bjartell A; Scardino PT; Lilja H
BMJ; 2013 Apr; 346():f2023. PubMed ID: 23596126
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]